Drug developer CEL-SCI plunges after unveiling stock offering

** Cancer drug developer CEL-SCI's shares plunge 19.5% to $10.50 in extended trading** CVM unveils proposed public offering of stock and pre-funded warrants; size not disclosed** Proceeds from offering will be used to fund continued development of Multikine - its treatment for head and neck cancer - and other purposes** ThinkEquity acting as sole placement agent for the offering** CVM has 6.9 million outstanding shares for $89.7 million market cap, per LSEG data** As of last close, CVM stock up 8.7% YTD